A LIMITED SAMPLING MODEL FOR THE PHARMACOKINETICS OF ETOPOSIDE GIVEN ORALLY

被引:35
作者
GENTILI, D
ZUCCHETTI, M
TORRI, V
SESSA, C
DEJONG, J
CAVALLI, F
DINCALCI, M
机构
[1] MARIO NEGRI INST PHARMACOL RES,VIA ERITREA 62,I-20157 MILAN,ITALY
[2] OSPED SAN GIOVANNI BELLINZONA,DIV ONCOL,CH-6500 BELLINZONA,SWITZERLAND
关键词
D O I
10.1007/BF00685894
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A limited sampling model of etoposide after oral administration to estimate the area under the plasma concentration-time curve from 0 to 24 h (AUC) by determination of the drug plasma levels at only two time points was developed by a multiple regression analysis on a training data set of 15 patients receiving oral doses ranging from 54 to 90 mg/m2. The equation describing the model is AUC (mug ml-1 h) = 5.183 (mug ml-1 h) + 1.193 (h) x C1h (mug/ml) + 8.439 (h) x C4h (mug/ml) (R2 = 0.93, P = 0.0001), where C1h and C4h represent the plasma etoposide concentrations at 1 and 4 h, respectively. The model was validated prospectively on a test data set of 13 patients receiving oral doses ranging from 52 to 87 mg/m2 and, additionally, on a data set of 7 patients receiving oral doses ranging between 176 and 200 mg/m2, investigated in a previous study. Validation on both test data sets gave a relative mean predictive error of 0.1% and a relative root mean square error of 15.8% and 16.7%, respectively. The present study shows that it is possible to obtain a good estimate of the plasma AUC after oral administration of etoposide using a two-time-point sampling model. The model can be used to monitor the etoposide AUC in patients receiving chronic oral treatment.
引用
收藏
页码:482 / 486
页数:5
相关论文
共 19 条
[1]   FITTING AUTOREGRESSIVE MODELS FOR PREDICTION [J].
AKAIKE, H .
ANNALS OF THE INSTITUTE OF STATISTICAL MATHEMATICS, 1969, 21 (02) :243-&
[2]  
CAVALLI F, 1978, CANCER TREAT REP, V62, P473
[3]  
CAVALLI F, 1991, EUR J CANCER S2, V27, P5194
[4]  
CLARK P, 1991, P AN M AM SOC CLIN, V10, P268
[5]  
CUNNINGHAM D, 1986, MED ONCOL TUMOR PHAR, V3, P95
[6]  
DINCALCI M, 1982, CANCER CHEMOTH PHARM, V7, P141
[7]  
EVANS WE, 1982, CANCER CHEMOTH PHARM, V7, P147
[8]   VARIABLE BIOAVAILABILITY FOLLOWING REPEATED ORAL DOSES OF ETOPOSIDE [J].
HARVEY, VJ ;
SLEVIN, ML ;
JOEL, SP ;
SMYTHE, MM ;
JOHNSTON, A ;
WRIGLEY, PFM .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (11) :1315-1319
[9]  
JOEL S P, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P178
[10]   PROLONGED ADMINISTRATION OF ORAL ETOPOSIDE IN PATIENTS WITH RELAPSED OR REFRACTORY SMALL-CELL LUNG-CANCER - A PHASE-II TRIAL [J].
JOHNSON, DH ;
GRECO, FA ;
STRUPP, J ;
HANDE, KR ;
HAINSWORTH, JD .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (10) :1613-1617